Trials / Unknown
UnknownNCT02184910
Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 108 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pepsinogen and gastrin |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2014-07-09
- Last updated
- 2019-03-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02184910. Inclusion in this directory is not an endorsement.